{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T09:48:28Z","timestamp":1779184108531,"version":"3.51.4"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000890","name":"National Multiple Sclerosis Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000890","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.msard.2020.102399","type":"journal-article","created":{"date-parts":[[2020,7,15]],"date-time":"2020-07-15T12:42:02Z","timestamp":1594816922000},"page":"102399","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"special_numbering":"C","title":["Clinical and laboratory features distinguishing MOG antibody disease from multiple sclerosis and AQP4 antibody-positive neuromyelitis optica"],"prefix":"10.1016","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5696-8841","authenticated-orcid":false,"given":"John R.","family":"Ciotti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noah S.","family":"Eby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory F.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert T.","family":"Naismith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salim","family":"Chahin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0829-7569","authenticated-orcid":false,"given":"Anne H.","family":"Cross","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.msard.2020.102399_bib0001","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/0165-5728(87)90031-2","article-title":"Antibody responses in chronic relapsing experimental allergic encephalomyelitis: correlation of serum demyelinating activity with antibody titre to the myelin\/oligodendrocyte glycoprotein (MOG)","volume":"17","author":"Linington","year":"1987","journal-title":"J. Neuroimmunol."},{"issue":"12","key":"10.1016\/j.msard.2020.102399_bib0002","doi-asserted-by":"crossref","first-page":"4016","DOI":"10.4049\/jimmunol.139.12.4016","article-title":"A monoclonal antibody against a myelin oligodendrocyte glycoprotein induces relapses and demyelination in central nervous system autoimmune disease","volume":"139","author":"Schluesener","year":"1987","journal-title":"J. Immunol."},{"issue":"12","key":"10.1016\/j.msard.2020.102399_bib0003","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1212\/WNL.0b013e31826aac4e","article-title":"Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype","volume":"79","author":"Kitley","year":"2012","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.msard.2020.102399_bib0004","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1084\/jem.20050304","article-title":"IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel","volume":"202","author":"Lennon","year":"2005","journal-title":"J. Exp. Med."},{"issue":"3","key":"10.1016\/j.msard.2020.102399_bib0005","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1001\/jamaneurol.2013.5857","article-title":"Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study","volume":"71","author":"Kitley","year":"2014","journal-title":"JAMA Neurol."},{"issue":"6","key":"10.1016\/j.msard.2020.102399_bib0006","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1212\/WNL.0000000000000101","article-title":"Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders","volume":"82","author":"Sato","year":"2014","journal-title":"Neurology"},{"issue":"12","key":"10.1016\/j.msard.2020.102399_bib0007","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1093\/brain\/awx276","article-title":"Clinical presentation and prognosis in MOG-antibody disease: a UK study","volume":"140","author":"Jurynczyk","year":"2017","journal-title":"Brain"},{"issue":"21","key":"10.1016\/j.msard.2020.102399_bib0008","doi-asserted-by":"crossref","first-page":"e1858","DOI":"10.1212\/WNL.0000000000005560","article-title":"Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: The MOGADOR study","volume":"90","author":"Cobo-Calvo","year":"2018","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.msard.2020.102399_bib0009","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1001\/jamaneurol.2018.4053","article-title":"Clinical, radiologic, and prognostic features of myelitis associated with myelin oligodendrocyte glycoprotein antibody","volume":"76","author":"Dubey","year":"2019","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.msard.2020.102399_bib0010","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.msard.2019.02.023","article-title":"Clinical characteristics of myelin oligodendrocyte glycoprotein antibody neuromyelitis optica spectrum disorder","volume":"30","author":"Salama","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2020.102399_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102005","article-title":"Clinical and immunological differences between MOG associated disease and anti AQP4 antibody-positive neuromyelitis optica spectrum disorders: Blood-brain barrier breakdown and peripheral plasmablasts","volume":"41","author":"Tanaka","year":"2020","journal-title":"Mult. Scler. Relat. Disord"},{"issue":"2","key":"10.1016\/j.msard.2020.102399_bib0012","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol."},{"issue":"10","key":"10.1016\/j.msard.2020.102399_bib0013","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1177\/1352458517721357","article-title":"Streamlined EDSS for use in multiple sclerosis clinical practice: development and cross-sectional comparison to EDSS","volume":"24","author":"Baldassari","year":"2018","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2020.102399_bib0014","article-title":"Clinical instrument to retrospectively capture levels of EDSS","volume":"39","author":"Ciotti","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"1","key":"10.1016\/j.msard.2020.102399_bib0015","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s00417-008-0926-0","article-title":"Resolving the clinical acuity categories \u201chand motion\u201d and \u201ccounting fingers\u201d using the Freiburg Visual Acuity Test (FrACT)","volume":"247","author":"Lange","year":"2009","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"issue":"1","key":"10.1016\/j.msard.2020.102399_bib0016","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate: a practical and powerful approach to multiple testing","volume":"57","author":"Benjamini","year":"1995","journal-title":"J. R. Stat. Soc."},{"key":"10.1016\/j.msard.2020.102399_bib0017","unstructured":"U.S. Census Bureau QuickFacts: Missouri. (n.d.). Retrieved March 30, 2020, fromhttps:\/\/www.census.gov\/quickfacts\/fact\/table\/MO\/PST045219."},{"issue":"5","key":"10.1016\/j.msard.2020.102399_bib0018","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1212\/WNL.53.5.1107","article-title":"The clinical course of neuromyelitis optica (Devic\u2019s syndrome)","volume":"53","author":"Wingerchuk","year":"1999","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.msard.2020.102399_bib0019","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.ophtha.2006.06.060","article-title":"Natural history of the visual impairment of relapsing neuromyelitis optica","volume":"114","author":"Merle","year":"2007","journal-title":"Ophthalmology"},{"issue":"10","key":"10.1016\/j.msard.2020.102399_bib0020","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1136\/jnnp.2007.143529","article-title":"Relapsing neuromyelitis optica: long term history and clinical predictors of death","volume":"80","author":"Cabre","year":"2009","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"1","key":"10.1016\/j.msard.2020.102399_bib0021","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1046\/j.1471-4159.1999.0720001.x","article-title":"The structure and function of myelin oligodendrocyte glycoprotein","volume":"72","author":"Johns","year":"1999","journal-title":"J. Neurochem."},{"issue":"11","key":"10.1016\/j.msard.2020.102399_bib0022","doi-asserted-by":"crossref","first-page":"3432","DOI":"10.1002\/(SICI)1521-4141(199911)29:11<3432::AID-IMMU3432>3.0.CO;2-2","article-title":"B cells are critical to induction of experimental allergic encephalomyelitis by protein but not by a short encephalitogenic peptide","volume":"29","author":"Lyons","year":"1999","journal-title":"Eur. J. Immunol."},{"issue":"3","key":"10.1016\/j.msard.2020.102399_bib0023","first-page":"443","article-title":"Augmentation of demyelination in rat acute allergic encephalomyelitis by circulating mouse monoclonal antibodies directed against a myelin\/oligodendrocyte glycoprotein","volume":"130","author":"Linington","year":"1988","journal-title":"Am. J. Pathol."},{"issue":"2","key":"10.1016\/j.msard.2020.102399_bib0024","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/5532","article-title":"Identification of autoantibodies associated with myelin damage in multiple sclerosis","volume":"5","author":"Genain","year":"1999","journal-title":"Nat. Med."},{"issue":"10","key":"10.1016\/j.msard.2020.102399_bib0025","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1001\/archneurol.2010.269","article-title":"Quantification and Functional Characterization of Antibodies to Native Aquaporin 4 in Neuromyelitis Optica","volume":"67","author":"Kalluri","year":"2010","journal-title":"Arch. Neurol."},{"issue":"2","key":"10.1016\/j.msard.2020.102399_bib0026","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/ana.410330203","article-title":"Multiple sclerosis: remyelination of nascent lesions","volume":"33","author":"Prineas","year":"1993","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2020.102399_bib0027","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1093\/brain\/awg045","article-title":"Chronic relapsing inflammatory optic neuropathy","volume":"126","author":"Kidd","year":"2003","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.msard.2020.102399_bib0028","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1186\/s12974-018-1335-x","article-title":"Chronic relapsing inflammatory optic neuropathy (CRION): a manifestation of myelin oligodendrocyte glycoprotein antibodies","volume":"15","author":"Lee","year":"2018","journal-title":"J Neuroinflam."},{"issue":"1","key":"10.1016\/j.msard.2020.102399_bib0029","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1001\/archneurol.2007.17","article-title":"Neuromyelitis optica and non-organ-specific autoimmunity","volume":"65","author":"Pittock","year":"2008","journal-title":"Arch. Neurol."},{"issue":"1","key":"10.1016\/j.msard.2020.102399_bib0030","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1177\/1352458511431077","article-title":"The emerging relationship between neuromyelitis optica and systemic rheumatologic autoimmune disease","volume":"18","author":"Wingerchuk","year":"2012","journal-title":"Mult. Scler."},{"issue":"3","key":"10.1016\/j.msard.2020.102399_bib0031","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1177\/1352458514564490","article-title":"A systematic review of the incidence and prevalence of autoimmune disease in multiple sclerosis","volume":"21","author":"Marrie","year":"2015","journal-title":"Mult. Scler."},{"issue":"3","key":"10.1016\/j.msard.2020.102399_bib0032","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1017\/neu.2016.49","article-title":"Frequency of autoimmune disorders and autoantibodies in patients with neuromyelitis optica","volume":"29","author":"Pereira","year":"2017","journal-title":"Acta Neuropsychiatr."},{"issue":"1\u20132","key":"10.1016\/j.msard.2020.102399_bib0033","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jns.2011.03.038","article-title":"Cerebrospinal fluid findings in aquaporin-4 antibody positive neuromyelitis optica: results from 211 lumbar punctures","volume":"306","author":"Jarius","year":"2011","journal-title":"J. Neurol. Sci."},{"issue":"16","key":"10.1016\/j.msard.2020.102399_bib0034","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1212\/WNL.0b013e3181f8832e","article-title":"IFN\u00df-1b may severely exacerbate Japanese optic-spinal MS in neuromyelitis optica spectrum","volume":"75","author":"Shimizu","year":"2010","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.msard.2020.102399_bib0035","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1177\/1352458512439439","article-title":"Does interferon beta treatment exacerbate neuromyelitis optica spectrum disorder","volume":"18","author":"Kim","year":"2012","journal-title":"Mult. Scler."},{"issue":"2","key":"10.1016\/j.msard.2020.102399_bib0036","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1001\/archneurol.2011.216","article-title":"Failure of natalizumab to prevent relapses in neuromyelitis optica","volume":"69","author":"Kleiter","year":"2012","journal-title":"Arch. Neurol."},{"issue":"1","key":"10.1016\/j.msard.2020.102399_bib0037","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1177\/1352458511431973","article-title":"Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder","volume":"18","author":"Min","year":"2012","journal-title":"Mult. Scler."},{"issue":"1","key":"10.1016\/j.msard.2020.102399_bib0038","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s12974-019-1525-1","article-title":"Evaluation of treatment response in adults with relapsing MOG-Ab-associated disease","volume":"16","author":"Cobo-Calvo","year":"2019","journal-title":"J. Neuroinflam."},{"issue":"2","key":"10.1016\/j.msard.2020.102399_bib0039","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1002\/ana.25648","article-title":"Comparison of the Response to Rituximab between myelin oligodendrocyte glycoprotein and aquaporin-4 Antibody Diseases","volume":"87","author":"Durozard","year":"2020","journal-title":"Ann. Neurol."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034820304740?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034820304740?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:50:34Z","timestamp":1761900634000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034820304740"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":39,"alternative-id":["S2211034820304740"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2020.102399","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical and laboratory features distinguishing MOG antibody disease from multiple sclerosis and AQP4 antibody-positive neuromyelitis optica","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2020.102399","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102399"}}